Thyroid Cancer Treatment
Thyroid Cancer Treatment
Treatment is built from three instruments: an operation, radioiodine, and hormone suppression. Which are used, and how much of the gland is removed, depends on the type, the size, the nodes and the age — and sometimes the right answer is to wait.
Treatment at a glance
The plan follows the type first and the stage second, because the type decides whether radioiodine works at all:
- Papillary carcinoma, under 1 cm — active surveillance on a fixed ultrasound schedule, or surgery if the nodule is close to the trachea, has high-risk features, or the patient prefers removal.
- Papillary or follicular carcinoma, 1–4 cm, no nodes — lobectomy or total thyroidectomy. Either can be oncologically correct, and the choice depends on the other lobe, the molecular result and what hormone replacement means for the patient.
- Differentiated carcinoma over 4 cm, or with nodes — total thyroidectomy with central compartment dissection, and lateral neck dissection where nodes are involved there.
- Distant spread, or invasive local disease — total thyroidectomy, radioiodine where the disease takes up iodine, and systemic therapy where it does not.
- Medullary carcinoma — total thyroidectomy with central neck dissection in every case, lateral dissection when indicated, and no radioiodine; RET results drive the drug options.
- Anaplastic carcinoma — urgent multidisciplinary treatment built around surgery where it is feasible, external beam radiotherapy and targeted therapy, with the airway secured first.
Active surveillance: when not operating is the right call
Papillary microcarcinoma — a cancer one centimetre or less, confined to the gland — is the clearest example of over-treatment in modern oncology, and active surveillance is the response to it. The reasoning is straightforward: a large proportion of these tumours never grow, some regress, and the operation needed to remove them carries a small but real risk to the voice and to calcium levels that a tumour which never behaves aggressively would never have caused.
Surveillance is not neglect. It means an ultrasound at defined intervals, with the tumour's dimensions recorded and compared, and a clear threshold at which surgery is triggered — usually growth of more than two millimetres in two dimensions, or a change in the ultrasound appearance of the nodule or its nodes. It is not appropriate for every small tumour: proximity to the trachea, a suspicious node, an aggressive cytological or molecular picture, or a patient who would rather not live with a known cancer all favour operating. The decision is made together, and it is reversible in either direction.
The operation: lobectomy or total thyroidectomy
Two operations cover the great majority of thyroid cancer. A lobectomy removes the half of the gland containing the tumour, plus the isthmus; a total thyroidectomy removes the whole gland. Neither is automatically the better operation, and the differences that matter are practical ones.
- Hormone replacement — after a lobectomy most patients need no tablets at all, because the remaining lobe takes over. After a total thyroidectomy, levothyroxine is lifelong.
- Radioiodine — iodine-131 only targets thyroid tissue, so it is used after a total thyroidectomy. A lobectomy closes that option unless the remnant is completed later.
- Follow-up marker — thyroglobulin becomes a reliable tumour marker only once all normal thyroid tissue is gone, which makes surveillance for recurrence more sensitive after a total thyroidectomy.
- A second operation later — if disease recurs in the other lobe of a patient who had a lobectomy, a completion thyroidectomy is needed, and it is a more delicate operation than the first.
Alongside the gland, the surgeon addresses the nodes and protects two structures. Central compartment dissection removes the nodes directly beneath and beside the gland and is standard when nodes are involved or when the tumour is large; lateral neck dissection is performed when imaging shows disease in the side of the neck. The recurrent laryngeal nerve is identified and monitored throughout, and the parathyroid glands — four small glands that sit on the back of the thyroid and control calcium — are identified and left with their blood supply intact wherever possible. Hypocalcaemia from inadvertent parathyroid removal is the complication patients notice most, and it is largely a matter of surgical technique.
Radioiodine: what it does and who it is for
Iodine-131 is taken up by thyroid cells, normal and malignant, and destroys them with local radiation. It is given as a capsule or a drink, it targets tissue that takes up iodine, and it is why the differentiated cancers are treated differently from medullary and anaplastic carcinoma — those types simply do not concentrate iodine.
There are two distinct uses. Remnant ablation destroys the small amount of normal thyroid tissue left after a total thyroidectomy, which both improves the value of thyroglobulin as a follow-up marker and treats microscopic disease in the gland bed. Adjuvant or therapeutic dosing treats known iodine-avid disease, in the neck or elsewhere. Before treatment, TSH is raised — either by withholding levothyroxine or with recombinant TSH — because thyroid cells take up iodine only when stimulated. Patients are then isolated for a few days while the radiation falls, and the practical arrangements around that isolation are part of the plan, not an afterthought.
Not every patient needs it. A small, completely resected papillary cancer with no nodes and no adverse features may need no radioiodine at all, and giving it anyway is a decision that should be justified rather than assumed. Conversely, roughly a third of advanced differentiated cancers eventually stop taking up iodine, and that state — radioiodine-refractory disease — is the point at which systemic therapy is considered instead.
Hormone replacement and TSH suppression
Levothyroxine does two jobs at once after thyroid surgery, and they are controlled by the same tablet. The first is replacement: the body no longer makes thyroid hormone, and without it the patient becomes hypothyroid. The second is suppression: thyroid cells, including differentiated cancer cells, are stimulated by thyroid-stimulating hormone, so holding TSH low reduces that stimulus.
The dose is a balancing act rather than a fixed prescription. Too little suppression may leave a stimulus to residual disease; too much suppresses TSH below the point the heart and bones tolerate well, raising the risk of atrial fibrillation and of osteoporosis in a patient who will take the tablet for decades. Recent practice therefore stratifies: intensive suppression for high-risk disease, and a target closer to the normal range for low-risk disease that has been treated completely. The right level is set by the risk of recurrence, and it is periodically reassessed rather than fixed for life at the first prescription.
Targeted therapy when iodine no longer works
Systemic therapy in thyroid cancer is not chemotherapy in the usual sense. It is directed at the specific drivers of the tumour, and it is used mainly in two settings: radioiodine-refractory differentiated disease, and advanced medullary or anaplastic carcinoma.
Multikinase inhibitors such as lenvatinib block the blood supply the tumour depends on and are the standard first-line systemic treatment for progressive radioiodine-refractory disease. They work, and they have side effects that need managing — blood pressure, fatigue, hand-foot skin reactions — which is why they are started and monitored by an experienced team rather than prescribed and left. Selective RET inhibitors have changed the outlook for advanced medullary carcinoma with a RET mutation, and for RET-fusion-positive differentiated disease. In BRAF V600E anaplastic carcinoma, combined BRAF and MEK inhibition can shrink a tumour rapidly enough to make surgery or local control possible where it previously was not.
External beam radiotherapy
External beam radiotherapy is used sparingly in thyroid cancer, because the thyroid sits close to the trachea, oesophagus and spinal cord, and because radioiodine does much of the same job more selectively. It has three established roles:
- Locally invasive disease that did not take up iodine, or that could not be completely removed at operation.
- Unresectable or residual disease in the neck where surgery has reached its limit.
- Anaplastic carcinoma, where it is part of the primary treatment rather than a later option, sometimes with intensity-modulated or stereotactic techniques to spare the surrounding structures.
The delivery technique matters more here than in most sites, because of what lies immediately around the target. Intensity-modulated radiotherapy shapes the dose around the trachea, oesophagus and cord, and stereotactic treatment is used for small, well-defined targets, including deposits in bone and lung.
How the decision is actually made
Thyroid cancer sits across more disciplines than most cancers, and the disagreements between them are real. Surgery wants a clear margin; endocrinology wants a TSH target that will not damage the heart; nuclear medicine needs a total thyroidectomy to be able to use iodine; the patient wants a scar they can live with and a voice that is unchanged. A single specialist working in sequence tends to resolve those tensions by default rather than by decision.
That is why the network reviews thyroid cancer as a team — thyroid surgery, endocrinology, nuclear medicine, pathology and radiology in one discussion, with a single written plan as the output. In practice it changes three things most often: whether a small tumour is operated on at all, whether the operation is a lobectomy or a total thyroidectomy, and whether radioiodine follows. Send complete records and the written assessment is returned within 48 hours of the file being complete.